Agoracom Blog Home

Posts Tagged ‘THC’

MCOA Finalizes Joint Venture Agreement With Bougainville Ventures in Washington State $MCOA.us

Posted by AGORACOM-JC at 1:16 PM on Tuesday, April 4th, 2017

15233 mcoa

  • Finalized the joint venture agreement with Bougainville Ventures, Inc. in Washington State
  • MCOA will invest $1 million in cash in a newly formed entity
  • Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility

BONSALL, CA–(Apr 4, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has finalized the joint venture agreement with Bougainville Ventures, Inc. (“BV”) in Washington State.

MCOA will invest $1 million in cash in a newly formed entity. Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility, which will accommodate a Tier-3 production and processing I-502 tenant that has decades of experience and a proven track record of consistency and quality. MCOA and BV will split equity and profits equally, 50/50.

As turnkey landlords, MCOA and BV will provide our I-502 tenant with a state-of-the-art facility that creates an ideal cultivation environment that they can move into and be fully operational on day one. This enables our tenants to focus on what they do best, producing top quality products and not worrying about maintaining their infrastructure.

Donald Steinberg, MCOA President and CEO, said, “This project will help to expand our operations as an ancillary business into the Washington State market. Achieving this milestone of closing this deal, as well as completing our PCAOB audit at the end of the first quarter are two more pillars of the strong foundation we are building for our shareholders.”

The execution of the agreement is the final step in formalizing the Letter of Intent that was publicly announced on February 15, 2017. This joint venture partnership is formed for the purpose of greenhouse construction, management and commercial leasing to I-502 licensed producers within Washington State only and not beyond its borders.

ABOUT BOUGAINILLE VENTURES, INC.

Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on high-density and high-yielding crops. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to tenant-growers and provides growing infrastructure, as well as landlord services for licensed I-502 producers and processors in the state of Washington.

SAFE HARBOR STATEMENT

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Namaste Enters Into Non-Binding LOI With CannMart, a Late Stage ACMPR Applicant $N.ca

Posted by AGORACOM-JC at 9:51 AM on Tuesday, March 21st, 2017

Nlogo

  • Entered into a non-binding letter of intent with Cannmart Inc.
  • Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations
  • CannMart submitted its application to become a “sales only” licensed producer of medical cannabis

VANCOUVER, BRITISH COLUMBIA–(March 21, 2017) –

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 

Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ)(OTCQB:NXTTF) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with Cannmart Inc. (“CannMart“) whereby Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“) (the “Contemplated Transaction“). In 2014, CannMart submitted its application to become a “sales only” licensed producer of medical cannabis (the “ACMPR Application“).

The Contemplated Transaction represents a significant strategic maneuver by Namaste in advance of the potential legalization and regulation of cannabis in Canada. The strategic rationale for the Contemplated Transaction includes:

  • Represents a logical expansion of the product portfolio and generates additional recurring revenue streams from existing and new customers throughout Canada. Creates a one-stop shopping platform for Canadian cannabis consumers;
  • Aligns with Namaste’s e-commerce capabilities and dataset of over 50,000 individuals in Canada, which represents a significant competitive advantage in terms of becoming one of the leading online retailers of cannabis;
  • Complements Namaste’s distribution expertise and relationships with the location of CannMart’s proposed facility enabling same day delivery in the Greater Toronto Area and 24-hour delivery within Canada. Namaste will seek to be the leading online retailer of cannabis in terms of fulfillment and customer service; and
  • Enhances the overall financial profile of the Company in terms of additional revenue and margin generation potential. Attractive non-cash purchase price based on comparable public companies within the industry.

CannMart’s ACMPR Application

CannMart’s ACMPR Application and proposed business model are unique in the industry as CannMart has applied only to sell and not produce medical cannabis. Under this model and subject to obtaining a licence from Health Canada, CannMart would have the ability to purchase wholesale medical cannabis from other licensed producers and sell to individual patients in accordance with the ACMPR.

The ACMPR Application has completed the “security clearance” stage and is currently in the “review” stage of the licensing process. CannMart’s proposed facility is a 4,000 sq. ft. industrial building located in Etobicoke, Ontario (the “Facility“). Pursuant to the LOI, the Company will assume all of the going forward liabilities and obligations of CannMart, including the remaining build-out costs needed to prepare the Facility for the final stages of the licensing process and the pre-licensing inspection.

Terms of the Contemplated Transaction

Upon execution of the LOI, Namaste paid $50,000 (the “Initial Payment“) in cash to CannMart’s counsel, to be held in trust and released upon closing of the Contemplated Transaction. If Namaste does not provide CannMart with notice of completion of its due diligence within 30 days of the execution of the LOI, the Initial Payment will become non-refundable. The parties anticipate signing a definitive agreement in mid-late April.

Consideration for the Contemplated Transaction will be satisfied with common shares in the capital of the Company. A portion of common shares of the Company will be issued on closing of the Contemplated Transaction, and the remaining common shares of the Company will be issued upon the occurrence of certain milestones. The share price shall be the five-day trailing volume weighted average price prior to the day on which the Company announces the Contemplated Transaction, subject to compliance with all stock exchange and regulatory requirements.

Clarus Securities Inc. is acting as financial advisor to Namaste in connection with the Contemplated Transaction.

Conditions to Closing

Closing of the Contemplated Transaction is subject to the following:

  • Completion of a definitive share purchase agreement containing representations, warranties and covenants customary in a transaction of this nature;
  • Completion of all financial and legal due diligence;
  • Execution of an employment or consulting agreement with each of CannMart’s existing team members for the purposes of the MMPR Application or longer;
  • Receipt of all director and shareholder approvals, if necessary, and requisite regulatory approvals of each party relating to the Contemplated Transaction;
  • Each of the current directors and officers of CannMart (other than as agreed to by Namaste) having delivered resignations and releases to CannMart; and
  • Such other documentation and closing conditions as are customary for transactions similar to the Contemplated Transaction.

Management Commentary

Mr. Sean Dollinger, President and CEO of Namaste, comments: “The acquisition of CannMart represents a significant strategic transaction for Namaste. One of the core competitive advantages of Namaste is the international customer list we have built, which enables us to enter markets with new product offerings and instantly generate revenues. The addition of consumables to our product offering in Canada is an excellent example of this competitive advantage and we see multiple opportunities to obtain additional licences in international jurisdictions where we have a strong customer foothold.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) – PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Discusses Clinical Program in New Interview with CFN Media

Posted by AGORACOM-JC at 9:19 AM on Tuesday, February 14th, 2017

Tbp large

  • Exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program
  • Interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer

SEATTLE, WA–(Feb 14, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.

Medical marijuana may be legal for roughly 60% of the U.S. population, but the cost of the drug remains prohibitive for many patients in need. Tetra Bio-Pharma aims to undergo FDA-sanctioned clinical trials for dried medical marijuana to secure prescription drug coverage from insurance companies.

Tetra Bio-Pharma held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in late January to advance its PPP001 clinical trial. During the meeting, the FDA provided all the necessary guidance on the design of a Phase I clinical trial on healthy volunteers and its overall development program. The meeting further demonstrates the agency’s willingness to continue the clinical trial to develop a dried marijuana prescription drug.

PPP001 is a dried cannabis product with 9.5% tetrahydrocannabinol (“THC”) and 2% cannabidiol (“CBD”) that is being developed as a prescription drug that will meet the FDA’s high bar for quality and manufacturing. The company’s goal is to be the first to achieve reimbursement from insurance companies for the cost of the prescription, which could prove to be a game-changer for would-be medical marijuana patients that cannot afford the drug.

Tetra Bio-Pharma recently partnered with Sante Cannabis in Montreal to assist in developing its clinical trials. As a leading private medical marijuana clinic, the organization has years of experience in educating patients and ensuring the optimal benefits. The company aims to leverage this expertise to ensure that its clinical trials are properly designed to achieve desired outcomes while helping achieve the organization’s goal of lowering costs for patients.

Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/tetra-bio-pharma-moves-closer-to-clinical-trials/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

 

Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with FDA on PPP001 $TBP.ca

Posted by AGORACOM-JC at 10:21 AM on Monday, January 30th, 2017

Tbp large

  • Completed its pre-IND meeting with the USA Food and Drug Administration  for its PPP001 dried cannabis drug product
  • Meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research
  • FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements

OTTAWA, ONTARIO–(Jan. 30, 2017) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).

The FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements. Dr. Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, commented “We could not be more pleased, as the FDA guidance gave us a clear path to progress from early to late phase clinical development. Adhering to the US FDA regulations is part of Tetra Bio-Pharma’s dedication to the commercialization of Cannabis as a prescription controlled drug and the corporations plan to seek reimbursement by insurers for patients.”

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 689-0714

Tetra Bio-Pharma Inc. Announces New Appointment of Dr. Gilles Chamberland, M.D., FRCPC to its Scientific and Clinical Advisory Board $TBP.ca

Posted by AGORACOM-JC at 9:15 AM on Wednesday, January 11th, 2017

Tbp large

  • Announced the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board
  • Board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development

(TORONTO, ONTARIO  Jan. 11, 2017) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), is pleased to announce the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development. The nomination of Dr. Chamberland, M.D., to its Advisory Board will provide critical guidance on PPP’s clinical development program with regards to the safety of cannabis drug products and the potential mental health risks associated with the consumption of marijuana.

“Patient safety has been a driving force since the creation of PPP. The use of cannabis has been associated with several important safety issues including potential psychiatric-related events. As a company focused on creating scientific data these risks, as well as others, must be adequately assessed and quantified in a clinical environment. The addition of Dr. Gilles Chamberland, M.D., FRCPC, to our team of accomplished scientific and clinical experts will help us ensure that these potential adverse effects of consuming cannabis will be adequately assessed in our clinical development program and these potential risks will be appropriately communicated to both physicians and patients”, stated Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs.

ABOUT Dr. Gilles Chamberland

Dr. Gilles Chamberland, M.D., FRCPC – Director Professional Services, Medical Psychiatrist, Associate Professor, Department of Psychiatry, Institut Philippe-Pinel de Montréal, Université de Montréal.

Dr. Chamberland received a Bachelor of Law degree from the Université de Sherbrooke, a doctorate in medicine from the Université de Montréal, a diploma in psychiatry from the Université de Montréal, and a diploma of advanced studies in biological and medical ethics of the René Descartes University in Paris. In 2012, he earned the Distinguished Fellow from the Canadian Psychiatric Association and, by 2015 the American Psychiatric Association gave him the same professional recognition. He received a diploma in the subspecialty of Forensic Psychiatry in 2013 from the Royal College of Physicians and Surgeons of Canada. Dr. Chamberland has a vast experience in clinical management of patients suffering from various psychiatric conditions including marijuana induced-psychosis. He is also a well-known author and expert witness in the field on psychiatry.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Tetra Bio-Pharma Inc.
Andre Rancourt, Chief Executive Officer, or
Ryan Brown. VP Business Development and Communications, or
Andre Audet, Executive Chairman
(343) 689-0714
Investors@tetrabiopharma.com

More than $1 billion of marijuana sold in Colorado in 2016 $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 4:23 PM on Tuesday, December 13th, 2016
Image result for cnn
  • Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.
  • Recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788

(CNN) It’s always 4/20 somewhere — at least in Colorado. The state’s marijuana shops have reached a massive new milestone: $1 billion in legal, regulated sales in the first 10 months of 2016.
Voters legalized marijuana in Colorado back in 2012, but the dispensaries didn’t open until 2014Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.

And the boom is still growing. According to new data from the state’s Department of Revenue, recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788.

Attorney Christian Sederberg, partner at Vicente Sederberg, played an integral part in Colorado’s Amendment 64, which legalized marijuana in the state. He is estimating that sales of pot will reach $1.3 billion by the end of this year, which could have a total economic impact of over $3 billion.
Designer marijuana boosts THC potency
Designer marijuana boosts THC potency 02:24
“This milestone continues to show that the cannabis industry in Colorado is an engine of growth for the economy, a job creator, and one of the biggest industries in the state,” Sederberg told CNN. “People were consuming cannabis before, but now they are buying it from tax-regulated businesses that are benefiting the economy. This has replaced an underground, illegal market.”
Sederberg says that marijuana has become one of the largest industries in Colorado, and certainly the fastest growing.
“From 2015 to 2016, there has been a 53% increase in retail sales and a 9% increase in medical sales,” he said. “Medical sales are growing at a much slower rate, but recreational sales will continue to grow in the double digits.”

All-time high

Marijuana sales in Colorado hit an all-time high in September 2016, generating $127.8 million, according to The Cannabist, a Colorado-based news site covering the industry. But October’s numbers are still sizable: Shops sold nearly $82.8 million of recreational cannabis and $35 million of medical marijuana.
Colorado has three different taxes on recreational marijuana — a standard 2.9% sales tax, a special 10% sales tax, and a 15% excise tax on wholesale transfers, which go towards schools. The state collected just over $6 million from the excise tax, bringing the yearly total to $49.7 million, The Cannabist tallied.
Of that, the first $40 million will go towards school construction projects, and any additional tax revenue from the excise tax will go directly to the state’s public school fund.
In this past election, California, Massachusetts, Nevada, and Maine all approved legal sales of recreational marijuana. Medical marijuana is now legal in more than half of US states. In total, marijuana sales could expand the national market to $21 billion by 2020. That is up from $5.7 billion last year and an expected $7.9 billion this year.
But in the eyes of the federal government, marijuana is still an illegal substance. The Drug Enforcement Administration classifies marijuana as a Schedule 1 drug, the same as heroin, LSD, and ecstasy.
Source: http://edition.cnn.com/2016/12/13/health/colorado-marijuana-sales-trnd/

Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001 $TBP.ca

Posted by AGORACOM-JC at 9:04 AM on Wednesday, November 23rd, 2016

Tbp large

  • Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit
  • FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

OTTAWA, ONTARIO–(Nov. 23, 2016) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.

The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration (“FDA“) had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research (“CDER“) as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, “As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product”. Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.

The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.

The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: “As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial”.

About PPP001-kit product

PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.

The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.

PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.

Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.

In Other News:

The Company has received $227,738 in exercised warrants for November 2016.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown – VP Business Development and Communications
Andre Audet – Executive Chairman
Dr. Guy Chamberland – Chief Scientific Officer
(613) 421-8402

Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, November 16th, 2016

Tbp_large

  • Effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market
  • Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”.

OTTAWA, ONTARIO–(Nov. 16, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.

Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors.

The Company’s common shares are listed for trading on the OTCPINK, a U.S. based securities trading system, under the symbol “GRPOF”. Tetra Bio-Pharma shares will continue to be traded on the Canadian Stock Exchange under its existing symbol “TBP”.

André Rancourt, Chief Executive Officer, commented, “We’re pleased to announce that our shares have become DTC eligible on the U.S. market and excited to bring our Company to the attention of the investment community in the U.S. We believe that GRPOF offers investors a unique opportunity to invest in a bio pharmaceutical cannabis company before entering clinical trials later this year.

In other company news

Website:

The Company is proud to announce that its website located at www.tetrabiopharma.com is now live. We encourage investors to sign up for news releases and notifications as more information is added to the website.

Industry Participation:

Dr. Guy Chamberland, Chief Scientific Officer and regulatory affairs, and Ryan Brown, co-founder and VP of Business Development, will be presenting at the World of Cannabis business summit in Las Vegas on November 16th 2016. Dr. Chamberland will be presenting as part of “the science of medical cannabis” program while Ryan Brown will be presenting at the “emerging brands investor pitch seminar” more info can be found at www.worldofcannabissummit.com.

Investor Relations:

The Company would like to inform investors that it has engaged Alpha Deal Group LLC, a New York based buy side analyst firm, to perform investor analysis for presentation to its investment network.

As released on November 9, 2016, via CFN (Cannabis Financial Network), the Company has engaged Cannabis Financial Network to increase its visibility in the United States retail investment market.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Phone: (613) 421-8402

Ryan Brown
Co-founder and Director of Communications
Phone: (613) 421-8402

Andre Audet
Executive Chairman
Phone: (613) 421-8402

V-Love(tm) now available in London Drugs stores

Posted by AGORACOM-JC at 9:06 AM on Monday, June 29th, 2015

  • V-LoveTM is now available for purchase in 30 London Drugs stores and is to be in all 79 stores by Friday July 3rd
  • First shipment of V-LoveTM to the London Drugs main distribution facility in Richmond, BC was received and is in the process of being redistributed to all London Drugs stores across Western Canada

VANCOUVER, BC / June 29 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce V-LoveTM is now available for purchase in 30 London Drugs stores and is to be in all 79 stores by Friday July 3rd.

The first shipment of V-LoveTM to the London Drugs main distribution facility in Richmond, BC was received and is in the process of being redistributed to all London Drugs stores across Western Canada.

V-LoveTM can also be purchased online at Londondrugs.com for your personal convenience and can be shipped anywhere in Canada.

V-LoveTM is pH balanced specifically for women and provides lubrication and a moisturizing feeling to sooth vaginal dryness.


Click Image To View Full Size

V-LoveTM It all begins with desire…

“We are very pleased to be in a growing number of stores and look forward to growing our V-Love TM brand name,” stated President Robert McAllister.

About Enertopia

The Company’s mission is to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that V-Love TM will have any meaningful impact on the Company or the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release